Corbus Pharmaceuticals Holdings Inc (CRBP)

In the past six months, Corbus Pharmaceuticals' stock has experienced several notable events and trends. As of late March 2026, the stock price had increased. The company reported its Q4 and full-year 2025 financial results on March 9, 2026, announcing a wider net loss for Q4 2025 and the full year, primarily due to increased clinical development spending. Despite the net loss, Corbus completed a $75 million public offering in Q4 2025, which bolstered its cash and investments to $163.3 million by the end of 2025, extending its cash runway into 2028. Positive clinical data readouts for CRB-701 and CRB-913 in Q4 2025 were highlighted. The company has participated in several investor and healthcare conferences. Insider selling has been observed over the last year. As of March 20, 2025, the stock had plummeted.

As a clinical-stage biopharmaceutical company with products still in development and not yet commercialized, there is no readily available information indicating demand seasonality for Corbus Pharmaceuticals Holdings, Inc.'s products or services.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity. Its pipeline includes CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4-expressing tumors; CRB-601, an anti-integrin monoclonal antibody for solid tumors (program deprioritized); and CRB-913, an orally delivered CB1 receptor inverse agonist for obesity.

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. The company has employees across three continents, including North America, Europe, and Asia, and aims to expand its presence in international markets through strategic partnerships and collaborations.

Corbus Pharmaceuticals has a "Moderate Buy" consensus rating from analysts. The company's news sentiment score is 1.67. A past class action lawsuit (dating from November 2016 to February 2019) impacted the company's reputation at the time.

Corbus Pharmaceuticals Holdings, Inc. has a diverse ownership structure. Major institutional owners include Cormorant Asset Management, LP, Orbimed Advisors LLC, Standard Life Aberdeen plc, Octagon Capital Advisors LP, Vanguard Group Inc, Citadel Advisors Llc, Prosight Management, LP, Armistice Capital, Llc, Stonepine Capital Management, LLC, and Renaissance Technologies Llc. Individual investors collectively hold a significant stake, accounting for 40% of the ownership. Cormorant Asset Management LP is also noted as the largest individual shareholder, owning 26.61% of the company's shares.